Leading partner in TechnoPhage Clinical Trial

Vector B2B – Drug Development has been elected as the lead partner to manage the TechnoPhage clinical trial on Diabetic Foot Ulcers. TechnoPhage trusted Vector B2B – Drug Development to conduct the TP-102_101/REVERSE study, a Phase I/IIa Double-Blind Randomized Clinical Trial to determine the safety and tolerability of the bacteriophage cocktail TP-102 in subjects with […]

VectorB2B will be at “Phage Futures Congress 2021”

We are very pleased to announce that our Head of CMC, Teresa Duarte, will be a special guest of Cellexus joining the Phage Futures Congress. Teresa will be participating in the panel session at Phage Futures, hosted by Adam Ostrowski, Technical Application Specialist at Cellexus. Other participants include Jonathan Kotula, Head of Science at Felix Biotechnology, Rodrigo […]

VectorB2B will be at “Infectious Diseases Virtual Partnering”

We are very pleased to be attending the Infectious Diseases Virtual Partnering from 2-4 December, 2020. If you have any questions, please contact our specialist. Vector B2B – Drug Development will present our new services available to all pharmaceutical & biotechnology companies developing new treatments for many infectious diseases for which there are not satisfactory preventive tools […]

VectorB2B team is now complete!

VectorB2B has been recruiting highly qualified HR with the knowledge and expertise to face all processes associated with research from the bench to the bedside. Now, the recruitment process has closed. The team is ready to go and prepared for all the exciting challenges underlying an association that offers state-of-the-art technologies and flexible services tailored-made […]